Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Neuroimaging Studies of Depression in Parkinson's Disease

This study has been completed.
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
Lee Blonder, University of Kentucky Identifier:
First received: August 16, 2007
Last updated: May 16, 2013
Last verified: April 2013
The purpose of this study is to investigate similarities and differences in the neural pathways of depressed Parkinson's patients, non-depressed Parkinson's patients, and healthy controls using magnetic resonance imaging (MRI) of the brain and neuropsychological assessment.

Parkinson's Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Neuroimaging Studies of Depression in Parkinson's Disease

Resource links provided by NLM:

Further study details as provided by Lee Blonder, University of Kentucky:

Estimated Enrollment: 120
Study Start Date: July 2006
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Patient Group
Control Group

Detailed Description:
Depression is a common and potentially serious complication of Parkinson's disease (PD). Studies show that approximately 40 percent of PD patients are depressed. There is evidence that these patients have deficits in neuropsychological function relative to non-depressed PD patients. Despite the widespread toll on emotional health posed by PD, few studies have undertaken a comprehensive examination of the neural underpinnings of Parkinsonian depression. In this project, we will compare depressed versus non-depressed Parkinson patients to a sample of demographically-matched healthy controls using neuropsychological assessment and magnetic resonance imaging (MRI). To investigate possible effects of anti-Parkinsonian medication on mood, cognitive function, and neural response, PD patients will be tested both off and on Parkinsonian medications.

Ages Eligible for Study:   40 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Neurology clinics, community sample

Inclusion Criteria:

  • right-handed
  • willing/able to undergo magnetic resonance imaging (MRI)

Exclusion Criteria:

  • history of neurological condition other than Parkinson's disease
  • history of psychiatric condition other than depression
  • history of substance abuse/dependence
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00518258

United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40536
Sponsors and Collaborators
Lee Blonder
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
Principal Investigator: Lee X. Blonder, PhD University of Kentucky
  More Information

Responsible Party: Lee Blonder, PI, University of Kentucky Identifier: NCT00518258     History of Changes
Other Study ID Numbers: R01-MH78228-2
Study First Received: August 16, 2007
Last Updated: May 16, 2013

Keywords provided by Lee Blonder, University of Kentucky:
Parkinson's Disease
Magnetic Resonance Imaging (MRI)
neuropsychological assessment

Additional relevant MeSH terms:
Parkinson Disease
Behavioral Symptoms
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases processed this record on May 25, 2017